Initial Statement of Beneficial Ownership (3)
January 27 2022 - 9:15AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Fogarty Krista |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/19/2022
|
3. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [LPCN]
|
(Last)
(First)
(Middle)
675 ARAPEEN DRIVE, SUITE 202 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Principal Accounting Officer / |
(Street)
SALT LAKE CITY, UT 84092
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | 12/7/2022 (1) | 12/7/2031 | Common Stock | 46000 | $1.12 | D | |
Stock Option (Right to Buy) | 12/15/2021 (2) | 12/7/2030 | Common Stock | 46000 | $1.37 | D | |
Stock Option (Right to Buy) | 1/28/2021 (3) | 1/28/2030 | Common Stock | 26000 | $0.458 | D | |
Stock Option (Right to Buy) | 12/4/2019 (4) | 12/4/2028 | Common Stock | 5000 | $1.46 | D | |
Stock Option (Right to Buy) | 10/22/2019 (5) | 10/22/2028 | Common Stock | 15000 | $1.13 | D | |
Explanation of Responses: |
(1) | Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. |
(2) | Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. |
(3) | Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 28, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. |
(4) | Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. |
(5) | Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of October 22, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Fogarty Krista 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY, UT 84092 |
|
| Principal Accounting Officer |
|
Signatures
|
/s/ Krista Fogarty | | 1/27/2022 |
**Signature of Reporting Person | Date |
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2023 to Apr 2024